Teresa Ramone1, Cristina Romei1, Raffaele Ciampi1, Alessia Tacito1, Paolo Piaggi1, Liborio Torregrossa2, Clara Ugolini2, Rossella Elisei3. 1. Department of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, Pisa, Italy. 2. Department of Surgical and Medical Pathology, Unit of Pathology, University of Pisa, Pisa, Italy. 3. Department of Clinical and Experimental Medicine, Unit of Endocrinology University of Pisa, Pisa, Italy. rossella.elisei@med.unipi.it.
Abstract
POURPOSES: We investigated the expression of RET9 and RET51 isoforms in medullary (MTC), papillary (PTC) thyroid carcinoma, normal thyroid tissues, and pheochromocytoma (PHEO) to verify if these isoforms are present also in follicular thyroid cell-derived tissues, and if there is a differential expression of RET9 and RET51 in MTC. METHODS: Nineteen patients with MTC, 18 patients with PTC, 18 samples of contralateral normal thyroid tissues, and 5 cases of PHEO were included in this study. RET isoform expression was studied by real-time RT-PCR. RESULTS: All MTCs and PHEOs were positive for RET9 and RET51. Fourteen/eighteen (77.7%) PTC cases were positive for RET9 and/or RET51, and four were positive for only one of the genes. In normal thyroid tissues, 3/18 (16.7%) cases were negative for both isoforms, 4/18 (22.2%) were positive for both, and 11/18 (61.1%) were positive for only one. RET isoforms were expressed at different levels in MTC, PHEO, PTC, and normal thyroid tissues: RET9 expression was higher in PHEO than in MTC, PTC, and normal thyroid tissues. RET9 expression was also higher in MTC than in PTC and normal thyroid tissues. No difference was observed between PTC and normal thyroid tissues. A similar pattern of expression was observed for RET51. In addition, RET51 was significantly more expressed than RET9 in MTC, while RET9 was the predominant isoform in PHEO. CONCLUSIONS: Our study documented the expression of the RET9 and RET51 isoforms in normal thyroid and PTC tissues. RET9 and RET51 isoforms were also present in MTC and PHEO. RET51 expression was higher than RET9 expression in MTC, while there was no difference in the expression of these two isoforms in PTC and normal thyroid tissues. RET9 was more highly expressed than RET51 in PHEOs.
POURPOSES: We investigated the expression of RET9 and RET51 isoforms in medullary (MTC), papillary (PTC) thyroid carcinoma, normal thyroid tissues, and pheochromocytoma (PHEO) to verify if these isoforms are present also in follicular thyroid cell-derived tissues, and if there is a differential expression of RET9 and RET51 in MTC. METHODS: Nineteen patients with MTC, 18 patients with PTC, 18 samples of contralateral normal thyroid tissues, and 5 cases of PHEO were included in this study. RET isoform expression was studied by real-time RT-PCR. RESULTS: All MTCs and PHEOs were positive for RET9 and RET51. Fourteen/eighteen (77.7%) PTC cases were positive for RET9 and/or RET51, and four were positive for only one of the genes. In normal thyroid tissues, 3/18 (16.7%) cases were negative for both isoforms, 4/18 (22.2%) were positive for both, and 11/18 (61.1%) were positive for only one. RET isoforms were expressed at different levels in MTC, PHEO, PTC, and normal thyroid tissues: RET9 expression was higher in PHEO than in MTC, PTC, and normal thyroid tissues. RET9 expression was also higher in MTC than in PTC and normal thyroid tissues. No difference was observed between PTC and normal thyroid tissues. A similar pattern of expression was observed for RET51. In addition, RET51 was significantly more expressed than RET9 in MTC, while RET9 was the predominant isoform in PHEO. CONCLUSIONS: Our study documented the expression of the RET9 and RET51 isoforms in normal thyroid and PTC tissues. RET9 and RET51 isoforms were also present in MTC and PHEO. RET51 expression was higher than RET9 expression in MTC, while there was no difference in the expression of these two isoforms in PTC and normal thyroid tissues. RET9 was more highly expressed than RET51 in PHEOs.
Entities:
Keywords:
Isoforms; Medullary thyroid carcinoma; Normal thyroid; Papillary thyroid carcinoma; RET
Authors: P Durbec; C V Marcos-Gutierrez; C Kilkenny; M Grigoriou; K Wartiowaara; P Suvanto; D Smith; B Ponder; F Costantini; M Saarma Journal: Nature Date: 1996-06-27 Impact factor: 49.962
Authors: M Rossel; A Pasini; S Chappuis; O Geneste; L Fournier; I Schuffenecker; M Takahashi; L A van Grunsven; J L Urdiales; B B Rudkin; G M Lenoir; M Billaud Journal: Oncogene Date: 1997-01-23 Impact factor: 9.867
Authors: O Fluge; D R Haugen; L A Akslen; A Marstad; M Santoro; A Fusco; J E Varhaug; J R Lillehaug Journal: Oncogene Date: 2001-02-15 Impact factor: 9.867
Authors: P Kjellman; D L Learoyd; M Messina; G Weber; A Höög; G Wallin; C Larsson; B G Robinson; J Zedenius Journal: Br J Surg Date: 2001-04 Impact factor: 6.939
Authors: T Iwashita; M Kato; H Murakami; N Asai; Y Ishiguro; S Ito; Y Iwata; K Kawai; M Asai; K Kurokawa; H Kajita; M Takahashi Journal: Oncogene Date: 1999-07-01 Impact factor: 9.867